Navigation Links
More radionuclide therapy is better for prostate cancer patients

Reston, Va. (November 1, 2011) For prostate cancer patients with bone metastases, repeated administrations of radionuclide therapy with 188Re-HEDP are shown to improve overall survival rates and reduce pain, according to new research published in the November issue of The Journal of Nuclear Medicine.

Approximately 50 percent of prostate cancer patients develop bone metastases that are predominately osteoblastic, that is, have the tendency to fracture resulting in serious morbidity. This type of bone metastasis often leads to chronic pain syndrome in prostate cancer patients; as many as 50 percent of prostate cancer patients with chronic pain syndrome are reported to receive inadequate pain treatment, which makes them candidates for radionuclide therapy.

The retrospective study, "Palliation and Survival After Repeated 188Re-HEDP Therapy of Hormone-Refractory Bone Metastases of Prostate Cancer: A Retrospective Analysis," reviewed cases of 60 patients with hormone-refractory prostate cancer. The patients, all of whom had more than five lesions documented by a bone scan, were divided into three groupsthose who received one therapy, two therapies or three or more therapies.

"Radionuclide therapy of bone metastases has been used for several decades for those with prostate cancer," noted lead author of the study Hans-Juergen Biersack, MD. "For this study, we developed 188Re-HEDP as a novel radiopharmaceutical whichdue to it is short half life of 19 hoursmakes sequential therapy possible."

The researchers found that post-treatment survival increased with the number of radionuclide therapies administered. Patients with progressive hormone-refractory prostate cancer receiving one therapy added 4.5 months, those receiving two therapies added 10 months, and those receiving three or more therapies improved their survival by 15.7 months. In addition, while the Gleason scoresa grading system used to evaluate the prognosis of men with prostate cancerfor each group were similar, the number of life-lost years for patients receiving three or more therapies was significantly lower.

In regards to pain reduction, no significant difference was found among those receiving 188Re-HEDP therapies. Pain reduction was achieved in 89.5 percent of those receiving one therapy, in 94.7 percent of those receiving two therapies and in 90.9 percent of those receiving three or more therapies.

"For patients failing chemotherapy or hormone treatments, 188Re-HEDP is a promising therapy that can both extend the number of survival years and help relieve pain from bone metastases," noted Biersack. "The findings support and expand the role of molecular therapy with radioisotopes in oncology."

188Re-HEDP is not commercially available and in-house production is required. 188Re-HEDP treatments for this study were developed at Oak Ridge National Laboratory in Oak Ridge, Tenn.


Contact: Susan Martonik
Society of Nuclear Medicine

Related medicine news :

1. Benefits of radionuclide therapy for neuroendocrine tumors
2. Radionuclide treatment against small tumors and metastases
3. New Multiple Sclerosis Therapy Promising in Early Trial
4. New therapy shows promise for treating cardiovascular disease
5. Speech Therapy Key to Stroke Rehab, But Many Miss Out
6. Scientists make strides toward drug therapy for inherited kidney disease
7. Ovarian Tumors May Develop Years After Fertility Therapy
8. Statin therapy fails to slow progression of atherosclerosis in pediatric lupus patients
9. Through-the-nipple breast cancer therapy shows promise in early tests
10. Compound found in common wart treatment shows promise as leukemia therapy
11. Timing for clinical trials for stem cell therapy in spinal cord injuries is right
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with ... Latin America . ... ... ... ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Volumes: Global Analysis (United States, China, Japan, Brazil, United ... to their offering. ... healthcare business planners, provides surgical procedure volume data in ... with an in-depth analysis of growth drivers and inhibitors, ...
Breaking Medicine Technology: